Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout

cafead

Administrator
Staff member
  • cafead   Jul 29, 2020 at 12:23: PM
via Amgen has culled a bispecific drug it picked up in a $1.7 billion biobucks deal with Xencor.

article source